2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Opioids, Women’s Health, Adverse Events, Biological Processes, Hematopoiesis, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Immunodeficiency, Infectious Diseases, Bacterial, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4702 Low HDL differs by genotype despite preserved LDL in adult women with sickle cell disease

Isabel Shrestha, BS, Hedayah Yehya, OMS-IV2, Ayesha Farooqui3, Judith Nocek4, Marwah Farooqui, DO5
1 University of Illinois College of Medicine, Chicago, United States
2 Midwestern University Chicago College of Osteopathic Medicine, Downers Grove, Illinois, United States
3 Massachusetts College of Pharmacy and Health Sciences, Boston, United States
4 University of Illinois College of Medicine, Chicago, United States
5 University of Illinois College of Medicine, Chicago, United States

Introduction: Adults with sickle cell disease (SCD) exhibit lipid abnormalities that differ from those seen in the general population, with low high-density lipoprotein cholesterol (HDL) being the most consistent finding. These changes are thought to reflect chronic hemolysis, inflammation, endothelial dysfunction, and altered lipid metabolism rather than traditional cardiometabolic dyslipidemia. However, lipid profiles among adult women across SCD genotypes remain poorly characterized. Because HDL concentrations differ by sex, studying women separately may better define SCD-associated lipid abnormalities. We hypothesized that women with HbSS would have lower HDL concentrations than those with HbSC. 

Methods: We conducted a retrospective cohort study using de-identified data from the University of Illinois Health System cohort of the Sickle Cell Disease Implementation Consortium Registry. Female participants aged ≥20 years with confirmed SCD and at least one available lipid panel were included, as routine lipid screening is generally recommended beginning in adulthood. The earliest available lipid panel was analyzed, prioritizing fasting HDL and LDL values when available. Parametric analyses were used for LDL and nonparametric analyses for HDL based on distribution testing. Lipid values were interpreted relative to contemporary U.S. population reference values. Lipid profiles were compared according to the SCD genotype, age group, body mass index (BMI), and certain cardiovascular comorbidities, and acute pain crisis burden. Multivariable linear regression analysis included HDL as the dependent variable and SCD genotype, age, BMI, and hydroxyurea use as independent variables. 

Results: 319 respondents were in the UIC cohort, with 179 identifying as female. Among these 179 participants, 78 women met inclusion criteria with at least one available lipid panel (mean age, 34.2±6.1 years); 62 (79.5%) had HbSS and 15 (19.2%) had HbSC. Low HDL was the predominant lipid abnormality, present in 85.3% of women (median 38 mg/dL), whereas elevated LDL was rare (1.4%). Median HDL was 38.0 mg/dL (interquartile range [IQR], 32.0-45.0), and median triglycerides were 90.5 mg/dL (IQR, 61.2-137.0). Women with HbSS had significantly lower HDL than those with HbSC (median, 37.0 [IQR, 30.8-44.0] vs 45.0 [IQR, 37.5-48.0] mg/dL; Mann-Whitney U, p =.034). No significant genotype differences were observed for total cholesterol, LDL, or triglycerides. 41 out of the 78 females (52.6%) presented with a BMI classified as overweight or obese. Lipid parameters did not differ across BMI categories, cardiovascular comorbidities, or acute pain-crisis burden, and BMI was not independently associated with HDL. No significant differences in lipid parameters were observed across age groups. In a multivariable linear regression model adjusting for SCD genotype, age, and BMI, hydroxyurea use was independently associated with a 6.95 mg/dL lower HDL level (95% CI, −12.13 to −1.77; p =.009).? 

Conclusion: Adult women with SCD demonstrated a lipid profile characterized by markedly reduced HDL despite generally preserved LDL concentrations. Women with HbSS had significantly lower HDL than those with HbSC, whereas HDL was not associated with age, BMI, cardiovascular comorbidities, or acute pain-crisis burden. These findings support the concept that HDL abnormalities in women with SCD are driven primarily by disease biology rather than traditional cardiometabolic risk factors. The association between hydroxyurea use and lower HDL likely reflects confounding disease severity, given its preferential use in patients with more severe disease. Prospective studies are needed to determine whether HDL may serve as a biomarker of SCD severity or vascular risk. 

Isabel Shrestha, BS: No relevant conflicts of interest to declare.